Core Viewpoint - The Chinese innovative drug industry is gradually catching up with Europe and the United States in terms of technology, with some targets and technical pathways already leading globally. The number and value of new drugs authorized for overseas markets continue to increase, leading to world-class pricing and non-linear investment elasticity. The domestic market is experiencing strong growth in demand, with domestic new drug sales continuing to rise, and several innovative pharmaceutical companies have turned losses into profits, entering a stable growth phase [2]. Group 1: Innovative Drugs - The innovative drug sector is witnessing a significant increase in sales driven by strong domestic demand, with a number of innovative companies achieving profitability [2]. - The trend of domestic innovative drugs going overseas is accelerating, with increasing numbers and values of new drug authorizations [2]. - The pricing power of innovative drugs is improving, reflecting the global competitiveness of Chinese pharmaceutical companies [2]. Group 2: High-Value Medical Consumables - The orthopedic sector is expected to see mild price reductions due to continued domestic substitution and accelerated overseas business progress [2]. - The neurosurgery and neurointervention fields are experiencing stable growth post-collection, with new products being launched [2]. - The high-value consumables market is expected to benefit from ongoing domestic replacement and the introduction of new products [2]. Group 3: Medical Devices - The medical device sector is seeing a recovery in bidding prices, with ongoing high-speed growth in bidding data this year [2]. - Companies are entering a phase of inventory reduction, with performance expected to improve in the second half of the year [2]. - The low-value consumables sector is experiencing product upgrades and accelerated expansion into overseas markets [2]. Group 4: Blood Products - The supply side of the blood products industry is concentrating on central state-owned enterprises, gradually clearing the competitive landscape [2]. - The demand side is expected to see continuous upgrades to new products, with industry sentiment gradually improving [2]. Group 5: API (Active Pharmaceutical Ingredients) - The API sector is benefiting from the end of a capital expenditure peak, with three growth logic points driving upward trends: new high-end market products, integrated consolidation and overseas expansion, and cost-leading CDMO [2]. - Leading companies in the API sector are expected to see explosive growth in revenue and profits [2]. Group 6: CXO (Contract Research Organization) - The CXO sector is witnessing a recovery in A+H financing activity, with multiple significant business developments enhancing market confidence [2]. - The focus is on optimizing the supply-side landscape and increasing market share for leading CRO companies [2]. Group 7: Traditional Chinese Medicine and Retail Pharmacy - The traditional Chinese medicine sector is showing signs of recovery, with friendly pricing for new drugs and ongoing observation of collection progress [2]. - The retail pharmacy sector is influenced by the pace of supply-side clearing and business model upgrades, with expectations of increased store closures in the second half of 2025 [2]. Group 8: Research and Development Services - The domestic innovative drug business development is heating up, likely driving downstream demand recovery [2]. - The overseas market presents significant growth opportunities for domestic companies, leveraging cost-effectiveness and service differentiation [2].

Group 1 - The core point of the article is that Kefu Medical announced the adjustment of its restricted stock incentive plan during a board meeting held on September 19, 2025, and provided details on its revenue composition for the first half of 2025 [1] - Kefu Medical's market capitalization is reported to be 8.1 billion yuan [2] - In the first half of 2025, Kefu Medical's revenue composition shows that medical health products accounted for 96.79% of total revenue, while other businesses contributed 3.21% [1]

第二届董事会第十八次会议决议公告 证券代码：301087 证券简称：可孚医疗 公告编号：2025-073 可孚医疗科技股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、会议召开情况 可孚医疗科技股份有限公司（以下简称"公司"）第二届董事会第十八次会 议于 2025 年 9 月 12 日以邮件方式发出会议通知，会议于 2025 年 9 月 19 日上午 9:30 以通讯方式召开。会议应出席董事 7 人，实际出席董事 7 人，公司高级管理 人员列席了会议。本次会议由董事长张敏先生主持。会议的召集和召开符合《中 华人民共和国公司法》等法律法规和《公司章程》的有关规定。 表决结果：同意 4 票，反对 0 票，弃权 0 票。公司董事张志明先生、薛小桥 1 先生、贺邦杰先生作为关联董事对本议案回避表决。 三、备查文件 二、董事会会议审议情况 与会董事对本次会议需审议的议案进行了充分讨论，审议通过了如下议案： 审议通过《关于调整 2024 年限制性股票激励计划相关事项的议案》 公司于 2025 年 9 月 10 日召开了 2025 年第三次临时股东大会，审议 ...

Core Viewpoint - The company has adjusted the grant price for its restricted stock incentive plan in response to the upcoming dividend distribution in 2025, ensuring compliance with relevant laws and regulations [1] Summary by Relevant Sections - **Incentive Plan Adjustment** The company has received necessary approvals for its 2024 restricted stock incentive plan adjustment, with the grant price reduced from 13.68 yuan per share to 13.10 yuan per share [1] - **Approval Process** Multiple board and supervisory meetings were held from March 2024 to September 2025 to review related proposals, confirming the company's adherence to procedural requirements [1] - **Legal Compliance** The legal opinion issued by Hunan Qiyuan Law Firm states that the adjustments made to the grant price are in line with applicable laws and the provisions of the company's incentive plan draft [1]

证券代码：301087 证券简称：可孚医疗 公告编号：2025-074 可孚医疗科技股份有限公司 关于调整 2024 年限制性股票激励计划相关事项的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 可孚医疗科技股份有限公司（以下简称"公司"）于 2025 年 9 月 19 日召开 第二届董事会第十八次会议，审议通过了《关于调整 2024 年限制性股票激励计 划相关事项的议案》，现将具体情况公告如下： 一、2024 年限制性股票激励计划已履行的相关审批程序 1、2024 年 3 月 1 日，公司召开第二届董事会第七次会议，会议审议通过了 《关于公司<2024 年限制性股票激励计划（草案）>及其摘要的议案》《关于公 司<2024 年限制性股票激励计划实施考核管理办法>的议案》《关于提请股东大 会授权董事会办理 2024 年限制性股票激励计划相关事宜的议案》等议案，律师 事务所、独立财务顾问出具相应报告。 同日，公司召开第二届监事会第七次会议，审议通过了《关于公司<2024 年 限制性股票激励计划（草案）>及其摘要的议案》《关于公司<2024 年限制性股 票激励 ...

湖南启元律师事务所 关于 可孚医疗科技股份有限公司调整 2024年限制性股票激励计划相关事项的 法律意见书 湖南启元律师事务所 关于可孚医疗科技股份有限公司 调整2024年限制性股票激励计划相关事项的 法律意见书 致：可孚医疗科技股份有限公司 湖南启元律师事务所（以下简称"本所"）接受可孚医疗科技股份有限公司（以 下简称"公司""可孚医疗"）的委托，作为特聘专项法律顾问为公司2024年限制性 股票激励计划项目（以下简称"2024年激励计划"）提供法律服务。 本所律师根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中 华人民共和国证券法》（以下简称"《证券法》"）、中国证券监督管理委员会（以 下简称"中国证监会"）《上市公司股权激励管理办法》（以下简称"《管理办法》"）、 《深圳证券交易所创业板股票上市规则》（2025年修订）（以下简称"《上市规 则》"）以及公司《2024年限制性股票激励计划（草案）》（以下简称"《2024 年激励计划》（草案）"）、《2024年限制性股票激励计划实施考核管理办法》 （以下简称"《2024年考核管理办法》"）等有关规定，按照律师行业公认的业务 标准、道德规范和勤勉尽责 ...

Core Viewpoint - The A-share market is witnessing a significant increase in cash dividends from listed companies, reflecting a strong willingness to return value to investors, with a total cash dividend amounting to 644.6 billion yuan in 2025, surpassing the previous year's figures [1] Group 1: Dividend Distribution - A total of 18 A-shares are set to distribute dividends on September 19, with 17 companies proposing cash dividends and one company planning to implement a combination of cash dividends, stock bonuses, or stock splits [1] - The companies with the highest proposed dividends include Xiamen Gibit Network Technology Co., Ltd. (66 yuan per 10 shares), Shandong Xintong Electronics Co., Ltd. (6 yuan), and Kewei Medical Technology Co., Ltd. (6 yuan) [1] - The "three major oil companies" (China National Petroleum Corporation, Sinopec, and CNOOC) plan to distribute over 800 billion yuan in total dividends, with China National Petroleum Corporation proposing 402.65 billion yuan [2] Group 2: Role of State-Owned Enterprises - State-owned enterprises (SOEs) are becoming the main contributors to dividend distributions, with the six major state-owned banks planning to distribute nearly 204.7 billion yuan, accounting for about 32% of the total dividend amount [3] - The increase in dividends from SOEs is driven by three main factors: clear policy guidance from the State-owned Assets Supervision and Administration Commission (SASAC), improved profitability structures in key industries, and the aim to stabilize investor confidence through high dividends [3] Group 3: Market Trends - The trend of listed companies in the A-share market opting for multiple dividends within a year is becoming more common, indicating a shift from a focus on financing to a focus on returns [4] - The optimization of investor structure, regulatory guidance on dividend ratios, and improvements in corporate governance are contributing to this shift towards a more return-oriented market environment [4]

Core Viewpoint - The stock of Kefu Medical (301087) has experienced a decline, with a closing price of 39.11 yuan on September 18, 2025, down by 2.05% [1] Financial Performance - Kefu Medical reported a main revenue of 1.496 billion yuan for the first half of 2025, a year-on-year decrease of 4.03% [3] - The net profit attributable to shareholders was 167 million yuan, down 9.51% year-on-year [3] - The net profit after deducting non-recurring gains and losses was 136 million yuan, a decline of 17.98% year-on-year [3] - In Q2 2025, the company achieved a single-quarter main revenue of 758 million yuan, an increase of 0.87% year-on-year [3] - The single-quarter net profit attributable to shareholders was 75.96 million yuan, down 9.3% year-on-year [3] - The single-quarter net profit after deducting non-recurring gains and losses was 67.67 million yuan, a decrease of 8.88% year-on-year [3] Market Position - Kefu Medical's total market capitalization is 8.17 billion yuan, ranking 47th in the medical device industry [3] - The company's net assets stand at 4.774 billion yuan, ranking 29th in the industry [3] - The net profit margin is 11.14%, ranking 61st in the industry [3] - The company has a price-to-earnings ratio of 24.4, significantly lower than the industry average of 67.82, ranking 21st [3] - The price-to-book ratio is 1.77, compared to the industry average of 3.91, ranking 28th [3] Stock Flow Analysis - On September 18, 2025, the net outflow of main funds was 1.1229 million yuan, accounting for 1.69% of the total transaction amount [1][2] - Retail investors showed a net inflow of 4.3936 million yuan, representing 6.6% of the total transaction amount [1][2] - Over the past five days, the stock has seen fluctuations in fund flows, with varying net inflows and outflows from different investor categories [2] Analyst Ratings - In the last 90 days, six institutions have rated Kefu Medical, with five giving a buy rating and one an increase rating [4] - The average target price set by institutions over the past 90 days is 45.0 yuan [4]

Group 1 - A-share listed companies are increasingly implementing mid-term dividends, with 18 companies announcing plans on September 18, 2025, and 17 of them proposing cash dividends [1] - The total cash dividend amount for 780 A-share companies in 2025 is projected to reach 644.6 billion, significantly higher than the previous year [1] - Companies like Xiamen Gibit Network Technology, Shandong Xintong Electronics, and Kewei Medical are among those with the highest proposed dividends, offering 66 yuan, 6 yuan, and 6 yuan per 10 shares respectively [1] Group 2 - State-owned enterprises (SOEs) are the main contributors to mid-term dividends, particularly in the energy, finance, and telecommunications sectors [2] - The three major telecom operators plan to distribute a total of approximately 74.26 billion in mid-term dividends, with China Telecom alone proposing 16.58 billion, representing 72% of its net profit [2] - The "three oil giants" are also generous in their dividend payouts, with a combined total exceeding 80 billion, including 40.27 billion from China National Petroleum [2] Group 3 - The six major banks in China, including Agricultural Bank and Industrial and Commercial Bank, are expected to distribute nearly 204.7 billion in dividends, accounting for about 32% of the total dividends [3] - The increase in dividends from SOEs reflects a policy shift by the State-owned Assets Supervision and Administration Commission (SASAC) to enhance profit distribution assessments [3] - The stable cash flow from SOEs in key sectors is attributed to their monopolistic positions, which provide consistent revenue streams [3] Group 4 - Local state-owned enterprises and leading manufacturing companies are also joining the mid-term dividend trend, indicating a broader acceptance of dividend distribution beyond traditional high-yield sectors [4] - Newly listed companies like Guangxin Technology and Kent Catalysts have also announced mid-term dividend plans, showcasing a shift in market practices [4] Group 5 - The trend of multiple dividends per year has become common in the A-share market, with a significant increase in mid-term dividend scales since 2024 [5] - The emphasis on dividend policies is seen as a way to enhance investor confidence and improve market image [5] - The shift from a focus on financing to returns reflects a deepening value investment philosophy, attracting long-term capital into the market [5] Group 6 - The increase in dividend payouts is a critical turning point in the capital market's transition from a focus on financing to one on returns [6] - The optimization of investor structure is driving improvements in dividend systems, with long-term funds prioritizing dividend yield over short-term performance [6] - Future integration of regular dividends with ESG disclosure mechanisms may accelerate the transformation of China's capital market into a value hub [6]

Core Viewpoint - The Chinese innovative drug industry is gradually catching up with Europe and the United States in terms of technology, with some targets and technical pathways already leading globally. The number and value of new drugs authorized for overseas markets continue to increase, leading to world-class pricing and non-linear investment elasticity. The domestic market is experiencing strong growth in demand, with domestic new drug sales continuing to rise, and several innovative pharmaceutical companies have turned losses into profits, entering a stable growth phase [2]. Group 1: Innovative Drugs - The innovative drug sector is witnessing a significant increase in sales driven by strong domestic demand, with a number of innovative companies achieving profitability [2]. - The trend of domestic innovative drugs going overseas is accelerating, with increasing numbers and values of new drug authorizations [2]. - The industry is positioned for a "Davis double" effect, where both performance and valuation are expected to improve [2]. Group 2: High-Value Medical Consumables - The orthopedic sector is expected to see mild price reductions, while domestic replacements continue to grow, and overseas business progresses rapidly [2]. - The neurosurgery and neurointervention fields are stabilizing after centralized procurement, with new products expected to contribute to growth [2]. Group 3: Medical Devices - The medical device sector is experiencing a high-speed growth in bidding data, with companies entering a destocking phase, which is expected to improve performance in the second half of the year [2]. - The low-value consumables sector is seeing continuous product upgrades and accelerated expansion into overseas markets [2]. Group 4: Blood Products - The supply side of the blood products industry is increasingly concentrated among state-owned enterprises, leading to a clearer competitive landscape [2]. - The demand side is expected to upgrade towards new products, gradually improving the industry's overall health [2]. Group 5: API (Active Pharmaceutical Ingredients) - The industry is at an upward turning point due to the end of a capital expenditure peak, combined with three growth drivers: new high-end market products, integrated consolidation and overseas expansion, and cost-leading CDMO [2]. - Leading companies are expected to see explosive growth in revenue and profits in the medium term [2]. Group 6: CXO (Contract Research Organization) - The CXO sector is seeing a revival in A+H financing activity, with multiple significant business developments enhancing market confidence [2]. - The focus is on optimizing the supply-side landscape and increasing market share for leading CRO companies [2]. Group 7: Traditional Chinese Medicine and Retail Pharmacy - The traditional Chinese medicine sector is showing signs of recovery, with friendly pricing for new drugs, while the retail pharmacy sector is influenced by supply-side adjustments and business model upgrades [2]. - The performance of offline pharmacies is expected to improve in the second half of 2025, with leading chains like YaoXingTang making progress in store upgrades [2]. Group 8: Research Reports - A series of in-depth research reports on various companies and sectors within the pharmaceutical and medical device industries have been published, highlighting their growth potential and market positioning [3][4].